Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Start With or Add Empagliflozin When The patient has established atherosclerotic cardiovascular disease, heart failure (any ejection fraction), chronic kidney disease with eGFR 20-45 mL/min, or the clinician is prioritizing cardiorenal protection alongside glucose control
If you experience joint pain whilst taking a GLP-1 medication, several practical strategies may help manage symptoms whilst you continue your prescribed treatment
Obesity is a complex, chronic medical disease, just like high blood pressure
Low Dose Naltrexone triggers a chemical reaction that manipulates two parts of your brain
This is where your handling protocol becomes the single most important factor in the success of your research
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors not yet approved by the MHRA or EMA as of April 2025
US$ 25.98
US$ 22.23
US$ 27.12
